In the long human struggle to name and treat the diseases that steal breath, researchers have found a hidden culprit: a single amino acid change in the WFDC2 gene that mimics cystic fibrosis so closely that patients have spent years without a true diagnosis. Identified primarily in Korean families, this mutation disrupts a protein that normally quiets overactive sodium channels in the lungs, leading to the same thick, suffocating mucus that defines cystic fibrosis — yet arising from an entirely different genetic origin. The discovery not only offers a name to those long without one, but points
WFDC2 Gene Mutation Linked to CF-Like Disease; Amiloride Shows Promise in Mice
Patients with WFDC2 mutations experience severe chronic airway disease with respiratory distress, bronchiectasis, and chronic rhinosinusitis.
A genetic mutation masquerading as cystic fibrosis, solved by a drug already in the medicine cabinet
Mark
Why does this mutation matter if we already have treatments for cystic fibrosis?
Mimi
Because this isn't cystic fibrosis. A patient with a WFDC2 mutation won't respond to CF therapies designed for CFTR defects. They've been getting the wrong treatment all along. Amiloride is simpler, cheaper, and already approved for other uses.
Mark
How certain are you that amiloride will work in people?
Mimi
The mouse data is compelling—it restored lung function. But mice aren't humans. We need clinical trials. What we know for sure is that the mechanism is real and the drug is safe. That's a strong foundation.
Mark
You said this is particularly common in Korean populations. Does that mean it's rare everywhere else?
Mimi
We don't know yet. This study identified it in Korean families, but that's partly because the researchers were looking there. Genetic variants don't respect borders. It could be present in other populations at frequencies we haven't measured.
Mark
What happens to someone with this mutation if they don't get treated?
Mimi
Progressive respiratory decline. Thickening mucus, recurrent infections, bronchiectasis—the lungs deteriorate. The mice without treatment developed respiratory failure. In humans, it would likely be a slow, chronic decline without intervention.
Mark
Is this the only WFDC2 variant that causes disease?
Mimi
This study found the p.C97W variant in five families. There could be others. The mechanism—impaired protein folding and ENaC hyperactivity—might apply to other WFDC2 mutations too. That's the next frontier.
Il Polso
- Patients with severe bronchiectasis and chronic sinusitis have been misdiagnosed for years — labeled with cystic fibrosis or primary ciliary dyskinesia — while the true cause, a WFDC2 gene mutation, went undetected.
- The p.C97W mutation causes the WFDC2 protein to misfold and become trapped inside cells, unleashing hyperactive sodium channels that strip moisture from airways and produce the dangerously thick mucus at the heart of the disease.
- Mouse models carrying the equivalent mutation developed respiratory failure, confirming the causal link and raising the urgency for a therapeutic response.
- Amiloride — a decades-old diuretic — blocked the overactive sodium channels in affected mice, dramatically improving survival and lung function, offering a repurposed drug as a near-term clinical hope.
- Genetic testing for WFDC2 variants is now recommended for anyone presenting with CF- or PCD-like symptoms, especially in Korean populations where the mutation appears at notably higher frequency.
In the long human struggle to name and treat the diseases that steal breath, researchers have found a hidden culprit: a single amino acid change in the WFDC2 gene that mimics cystic fibrosis so closely that patients have spent years without a true diagnosis. Identified primarily in Korean families, this mutation disrupts a protein that normally quiets overactive sodium channels in the lungs, leading to the same thick, suffocating mucus that defines cystic fibrosis — yet arising from an entirely different genetic origin. The discovery not only offers a name to those long without one, but points toward amiloride, an existing and well-tolerated drug, as a potential treatment already waiting in the medicine cabinet of history.
Researchers have identified a genetic mutation that produces a disease nearly indistinguishable from cystic fibrosis, offering long-overdue answers to patients who have been misclassified or left without a diagnosis. The variant — a change in the WFDC2 gene at position 97, where cysteine becomes tryptophan — was found in five unrelated Korean families after scientists sequenced the DNA of 64 patients presenting with severe bronchiectasis and chronic sinus inflammation. It appeared in roughly one in five of the families studied, a frequency striking enough to signal a genuine genetic cause.
WFDC2 is a protein produced in the cells lining the lungs, where it normally acts as a brake on ENaC, a sodium channel on the surface of airway cells. When the mutation is present, the protein misfolds, becomes trapped inside cells, and cannot perform this regulatory role. Without it, ENaC grows hyperactive — driven by elevated levels of a protease called PRSS8 — causing excessive sodium and water to be pulled from the airway surface. The result is the same thick, sticky mucus that clogs the lungs in cystic fibrosis, though produced by an entirely different genetic mechanism.
To confirm the link, researchers engineered a mouse model carrying the equivalent mutation. The animals developed respiratory failure mirroring the human disease — and then revealed something clinically valuable: treatment with amiloride, a drug that blocks ENaC and has been used safely for decades as a diuretic, significantly improved their survival and restored respiratory function.
The implications reach beyond biology. Many patients carrying this mutation have likely been living under incorrect diagnoses, receiving treatments calibrated to the wrong disease. Genetic testing for WFDC2 variants is now recommended for anyone with CF- or PCD-like presentations, particularly in populations where the mutation is more prevalent. For those who test positive, amiloride represents a therapeutic option already proven safe in other contexts — a treatment hiding in plain sight, waiting only for the right diagnosis to unlock it. Clinical trials in humans are the critical next step.
Researchers have identified a genetic mutation that causes a disease nearly indistinguishable from cystic fibrosis, opening a new diagnostic pathway for patients who have long been misclassified or left without answers. The culprit is a variant in the WFDC2 gene—specifically a change at position 97 where a cysteine amino acid becomes tryptophan, written as p.C97W. Scientists discovered this mutation in five unrelated families, all of Korean descent, after sequencing the DNA of 64 patients from 62 families who presented with severe bronchiectasis and chronic inflammation of the sinuses and nasal passages.
The finding emerged from a systematic genetic hunt. Using whole-exome and whole-genome sequencing, researchers identified pathogenic variants in roughly one in five of the families studied. The WFDC2 mutation stood out because it appeared in multiple unrelated families with strikingly similar disease presentations—a hallmark of a genuine genetic cause. WFDC2 is a protein normally produced in the cells that line the lungs. When the p.C97W mutation is present, the protein misfolds and cannot be secreted properly, leaving it trapped inside cells and unable to do its job.
The consequences of this malfunction ripple through the lung's delicate chemistry. WFDC2 normally acts as a brake on a sodium channel called ENaC, which sits on the surface of airway epithelial cells. When WFDC2 is absent or dysfunctional, ENaC becomes hyperactive. This overactivity is driven by increased levels of a protease called PRSS8. The result is excessive sodium and water reabsorption from the airway surface, leading to thick, sticky mucus that clogs the lungs—the same pathological cascade seen in cystic fibrosis, though triggered by a different genetic defect.
To confirm this mechanism, researchers created a mouse model carrying the equivalent mutation. These animals developed respiratory failure that mirrored the human disease, validating the causal link. But the mice also revealed something clinically promising: when treated with amiloride, a drug that blocks ENaC, their survival improved and their respiratory function recovered. Amiloride is not new—it has been used for decades as a diuretic and potassium-sparing agent. The discovery that it could rescue respiratory function in these mice suggests a ready-made therapeutic option for patients carrying the WFDC2 mutation.
The clinical implications are significant. Patients with WFDC2 mutations have been experiencing severe airway disease—bronchiectasis, chronic sinusitis, progressive respiratory decline—without a clear genetic diagnosis. Many may have been labeled as having cystic fibrosis or primary ciliary dyskinesia, conditions with different underlying causes and sometimes different treatment approaches. Now, genetic testing for WFDC2 variants is recommended for anyone presenting with CF-like or PCD-like symptoms, particularly in populations where the mutation appears more common. For those who test positive, amiloride offers a potential therapeutic avenue that has already been proven safe in other clinical contexts.
The work underscores how rare genetic variants can masquerade as common diseases and how precision medicine—matching diagnosis to underlying biology—can unlock treatments hiding in plain sight. The next step will be clinical trials to determine whether amiloride delivers the same benefit in humans that it showed in mice, and whether other WFDC2 variants follow the same pathological pathway.
Citazioni salienti
The p.C97W variant in WFDC2 is a critical genetic factor in severe chronic airway disease that shares clinical features with CF and PCD— Study authors
Vuoi la storia completa?
Leggi l'originale su nature.com ↗
Health & Medicine